Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer
- 1 April 1995
- Vol. 45 (4) , 633-640
- https://doi.org/10.1016/s0090-4295(99)80055-7
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancerCancer, 1993
- The use of flutamide in hormone-refractory metastatic prostate cancerCancer, 1993
- Some statistical considerations for the interpretation of trials of combined androgen therapyCancer, 1993
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- Challenges in the Management of Prostate CancerPublished by Wiley ,1992
- A Clinician's Guide to Cost-Effectiveness AnalysisAnnals of Internal Medicine, 1990
- Cancer statistics, 1990CA: A Cancer Journal for Clinicians, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Decision AnalysisNew England Journal of Medicine, 1987
- The Markov Process in Medical PrognosisMedical Decision Making, 1983